Safety and Efficacy of RK0202 in Oral Mucositis

PHASE2CompletedINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

January 31, 2003

Study Completion Date

December 31, 2005

Conditions
Mouth DiseasesMouth UlcersOral MucositisHead and Neck Cancer
Interventions
DRUG

RK-0202

Trial Locations (9)

33612

H Lee Moffitt Cancer Center & Research Institute, Tampa

40207

Commonwealth ENT, Louisville

43614

Medical University of Ohio, Cancer Institute Ruppert Cancer Center, Toledo

77030

MD Anderson Cancer Center, Houston

90095

UCLA Medical Center, Los Angeles

06030

University of Connecticutt, Farmington

T6G1Z2

Cross Cancer Institute, Edmonton

L8V5C2

Juravinski Cancer Center, Hamilton

K1H1C4

University of Ottawa, Ottawa

All Listed Sponsors
lead

RxKinetix

INDUSTRY

NCT00230191 - Safety and Efficacy of RK0202 in Oral Mucositis | Biotech Hunter | Biotech Hunter